Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3461-3480 of 3,900 trials

Healthy Adults: Effect of High-Fat Meal on DO-2

We are studying how a high-fat meal influences the way the medication DO-2 is absorbed in healthy individuals. This research may help us understand the best way to use this treatment.

Healthy Volunteers6-12 monthsSafety phase (I)Internal Medicine

Bloodstream Infections: PipEracillin Tazobactam vs. Meropenem

We are studying whether PipEracillin Tazobactam is as effective as Meropenem for treating bloodstream infections caused by certain resistant bacteria. This trial is for patients with infections from these specific bacteria.

Bacteremia1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Lung Cancer Treatment: Telisotuzumab Adizutecan with Osimertinib

We are studying a new combination treatment for adults with advanced EGFR-mutated non-small cell lung cancer. The goal is to see if this approach is safer and more effective than current standard treatments.

Non-Small Cell Lung Cancer6-12 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Hydroxychloroquine for Mastocytosis Symptoms

We are studying whether hydroxychloroquine can help reduce itching and flushing in patients with isolated cutaneous mastocytosis or indolent systemic mastocytosis with skin involvement. The trial also looks at other symptoms and how well patients tolerate the treatment.

Mastocytosis>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesDermatologyInternal Medicine

Ulcerative Colitis: MK-7240 Treatment Study

We are studying MK-7240 to see if it helps people with moderately to severely active ulcerative colitis achieve remission. The trial will also evaluate the safety and effectiveness of this new treatment compared to a placebo.

Ulcerative Colitis1-2 yearsConfirmation phase (III)Monitoring phase (IV)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterology

Clostridioides difficile Infection: Shorter Vancomycin Treatment

We are studying whether a 5-day course of oral vancomycin is as effective as the standard 10-day treatment for Clostridioides difficile infection. This trial will also assess recovery rates and safety for participants.

Clostridioides difficile Infection6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesGastroenterologyInfectious Diseases

Schizophrenia and Alcohol Use Disorder: Tirzepatide Study

We are investigating whether tirzepatide can help reduce alcohol consumption in individuals with schizophrenia and alcohol use disorder. This study compares tirzepatide to a placebo to assess its effects.

Schizophrenia and Alcohol Use Disorder6-12 monthsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyPsychiatry

NTS-521: Safety Study in Adults and Elderly

We are investigating how safe different doses of NTS-521 are for adults and elderly individuals. The study looks at how the body reacts to the drug and how the drug is processed over time.

Healthy ParticipantsSafety phase (I)Internal MedicineNeurology

Nebivolol for High Blood Pressure in Teens

We are studying how well Nebivolol works to lower blood pressure in adolescents with hypertension. The trial will also look at the safety of this medication during treatment.

Juvenile Hypertension6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Prostate Cancer Treatment: Docetaxel vs. Androgen Receptor-targeted Agents

We are studying whether docetaxel is more effective than abiraterone or enzalutamide for men with advanced prostate cancer and specific negative prognostic factors. This research aims to improve treatment outcomes and quality of life.

Metastatic Castration-Resistant Prostate CancerMonitoring phase (IV)No PlaceboStandard MedicinesOncologyUrology

Dravet Syndrome: EPX-100 Treatment Study

We are testing a new medication, EPX-100, to see if it helps children and adults with Dravet Syndrome manage their seizures better than a placebo. This study aims to find out if this treatment can be a useful addition to their current care.

Dravet Syndrome3-6 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesNeurologyPediatrics

Gastroesophageal Cancer: Sertraline with Immunochemotherapy

We are studying whether adding sertraline can enhance treatment responses in patients with advanced gastroesophageal cancer receiving immunochemotherapy. The trial also looks at safety, quality of life, and depression during treatment.

Gastroesophageal Cancer>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPsychiatry

Advanced Non-Small Cell Lung Cancer: H1-Antihistamine with Immunotherapy

We are studying whether adding an H1-antihistamine to immunotherapy can improve treatment response in patients with advanced non-small cell lung cancer.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Liraglutide: Effects on Digestion and Hunger

We are studying how liraglutide affects digestive activity and hunger in healthy volunteers. This research may help us understand its potential benefits for managing appetite.

Obesity1-2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesEndocrinologyGastroenterology

Cholangiocarcinoma: Chemo and Immunotherapy Study

We are exploring a combination of chemotherapy and immunotherapy for patients with locally advanced cholangiocarcinoma before surgery. The study aims to see if this approach can lower the risk of cancer returning after treatment.

Cholangiocarcinoma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Critical Limb Ischemia: L-PRF Treatment Study

We are investigating the safety of a new treatment using patient-derived fibrin for individuals with critical limb ischemia. The study also looks at its potential effects on limb health and quality of life.

Critical Limb Ischemia>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Glioblastoma: Dendritic Cell Immunotherapy Study

We are evaluating a new immune therapy for patients with glioblastoma to see if it improves survival and quality of life compared to standard treatments.

Glioblastoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesOncology

Alzheimer's Disease: The ExPlas Study on Plasma Transfusions

We are investigating whether plasma from exercise-trained donors is safe and can improve cognitive function in people with early Alzheimer's disease. This study will help us understand its effects over several years.

Early Symptomatic Phase Alzheimer's Disease>2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesInternal MedicineNeurology

Idiopathic Infertility: Metformin Treatment Study

We are investigating whether metformin can improve endometrial function in women with idiopathic infertility. This study aims to explore its effects on fertility and related biological markers.

Female Infertility3-6 monthsEfficacy phase (II)Standard MedicinesEndocrinologyGynecology and Obstetrics

Acute Cholecystitis: Indocyanine Green in Surgery

We are testing whether indocyanine green can help reduce surgery time and improve safety during gallbladder removal in patients with acute cholecystitis. This study aims to enhance surgical outcomes and patient satisfaction.

Acute Cholecystitis>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOrthopedics and Traumatology